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KwaZulu-Natal. Funders will have to assume responsibility for
morbidity and mortality of patients with meningococcal
septicaemia for whom they choose to deny treatment with
DroAA.
DroAA has been used in South Africa to treat patients with
severe sepsis whoare potentially salvageable but failing to
improve or deteriorating despite best supportive care . The
proviso that patients be deteriorating is a pragmatic stance
taken by intensivists in South Africa to make sure that only the
most deserving patients receive the agent. These patients are
also required to meet the inclusion and exclusion criteria for
the PROWESS trial' Best supportive care will include
appropriate source control and inotropes, lung protective
ventilation, insulin and steroids as appropriate, nutrition,
infection control, appropriate antibiotics and high-quality
nursing care .' This care is best supervised by an intensivist .
Despite the assertion of Taylor and Burns that there is a
shortage of intensivists in South Africa, the undersigned all
provide intensivist services in private hospitals throughout
South Africa . We do not only care for our own patients but are
available to provide advice to non-intensivist colleagues . We
are all deeply aware of the impact that excessive and
inappropriate use of DroAA will have on funders such as
Medscheme. However, the fear of this use has not been borne
out by clinical practice under intensivist supervision . None of
the undersigned has treated more than three patients with APC
since its release 8 months ago. Given the cost of other
interventions such as cancer chemotherapy and coronary
bypass surgery this hardly seems excessive or likely to impact
significantly on Medscheme'' ability to provide care for its
beneficiaries . We would like to appeal to Medscheme and other
funders that DroAAnot be withheld from patients deemed
appropriate by intensivists .
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Nocturnal enuresis guidelines
To the Editor. The authors and Ferring are to be congratulated on
their efforts in producing a useful document to aid practitioners
in the management of nocturnal enuresis and to publicise the fact
that treatment is widely available.'
However, I feel it is inappropriate to condemn the use of
tricyclic antidepressants in the treatment of this condition.
Caution is understandable, but in my 15 years of treating a large
number of enuretic children at Red Cross War Memorial
Children's Hospital and in private practice in Cape Town, I have
yet to come across a serious, irreversible side-effect related to the
use of these drugs. It is true that side-effects do occur, and
patients have to be counselled . It is also true that overdosage
with desmopressin (DDAVP) can result in fluid overload and
hyponatraemia, a potentially lethal side-effect.
One side-effect of DDAVPcompared with imipramine, which
the authors did not mention, is that of impoverishment . I
surveyed three local pharmacies and found the average price of a
month's supply of DDAVP0.2 mg tablets to be 8710.92 compared
with 8105.00 for Tofranil 25 mg and 829.26 for an imipramine
generic . Most families would find it difficult to find R700 per
month to spend on treatment of what is, in the authors' own
words, a non-lethal disorder, even for a limited period.
Concerning the enuresis alarm, it is my experience that while
this certainly is the best treatment, its use requires remarkable.
dedication on the part of the parents and the child as well as a
degree of insight, understanding and acceptance of the condition
that unfortunately does not exist in all families. Many parents are
still of opinion that enuresis is caused by laziness or naughtiness,
and a harsh and disciplinarian attitude is adopted.
Imipramine increases functional bladder capacity and
improves arousal from sleep in response to a full bladder, two of
the three components of the three-part model of enuresis
presented by the authors. It is not a perfect drug, but it
nevertheless deserves a place in the management of
monosymptomatic nocturnal enuresis in South Africa .
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